Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Aditya Raghunath

Up 68% in 1 Year, Is Novo Nordisk Stock Still a Buy?

Shares of healthcare giant Novo Nordisk (NVO) have been on an absolute tear in the last year, rising 68.9% in the last 12 months. Valued at a market cap of $579 billion, Novo Nordisk has returned over 7,800% to shareholders, after adjusting for dividends, since March 2004. 

Novo Nordisk is engaged in the research and development, manufacture, and distribution of healthcare products in Europe and other international markets. It has two primary business segments: Diabetes and Obesity Care, and Rare Diseases. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.